C17:1, another form of ginkgolic acid, was found to act as an effective suppressor of EGFR to sufficiently suppress tumor growth and invasion in human renal cancer 786-O and A498 cells (10–20 μM in vitro or 10 mg/kg twice per week for 6 weeks) and in human hepatoblastoma HepG2 cells (20–40 μg/mL in vitro or 40–80 mg/kg every other day for 2 weeks), by downregulating the EGFR/Akt/Erk signaling pathway [22,23]. Here, AKT1 is linked to neoplasm.